Lupin launches generic Pulmicort Respules

5/28/2019
Lupin is introducing its generic Pulmicort Respules (budesonide inhalation suspension). The company's generic of AstraZeneca's branded product will be available in 0.5 mg/2 ml single-dose ampules, having received the Food and Drug Administration's ok earlier.

The drug is indicated for the maintenance treatment of asthma and as prophylactic therapy in children from ages 12 months to 8 years old.

Budesonide inhalation suspension, 0.5 mg/2 ml single-dose ampules had a market value of approximately $385.4 million, according to IQVIA March 2019 data.
X
This ad will auto-close in 10 seconds